Ticker Details
Coherus BioSciences, Inc. Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.
IPO Date:	November 6, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$272.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 3.12%
Avg Daily Range (30 D):	$0.08 | 3.99%
Avg Daily Range (90 D):	$0.06 | 3.93%

Institutional Daily Volume
Avg Daily Volume:	1.15M
Avg Daily Volume (30 D):	2.76M
Avg Daily Volume (90 D):	1.69M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	281
Avg Trade Size (Sh.) (90 D):	284

Institutional Trades
Total Institutional Trades:	3,197
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$.54M
Avg Institutional Trade (90 D):	$1.02M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$.54M
Avg Closing Trade (90 D):	$.53M
Avg Closing Volume:	158.9K

News

Feb 17, 2026 @ 9:11 PM Coherus Oncology, Inc. Announces Closing of Public... Source: Globe Newswire

Feb 13, 2026 @ 2:18 AM Coherus Oncology, Inc. Announces Pricing of Public... Source: Na

Nov 6, 2025 @ 6:54 PM Arvind Sood joins Coherus Oncology as Chief Strate... Source: Denny Lanfear

Apr 1, 2025 @ 12:00 PM Coherus Announces Repurchase of Approximately $170... Source: Coherus Biosciences, Inc.

Jul 30, 2024 @ 5:00 PM Hepatic Tumor Clinical Trial Pipeline Experiences ... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1.33	$-.31	$2.57
Diluted EPS	$1.33	$-.31	$2.57
Revenue	$277.73M	$11.57M	$10.25M
Gross Profit	$156.38M	$7.85M	$6.86M
Net Income / Loss	$154.97M	$-35.53M	$297.77M
Operating Income / Loss	$-92.65M	$-44.33M	$-45.49M
Cost of Revenue	$121.35M	$3.72M	$3.4M
Net Cash Flow	$5.64M	$-113.56M	$134.48M
PE Ratio	0.00